Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc.verified

CKPT

Price:

$3.54

Market Cap:

$170.39M

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a tre...[Read more]

Industry

Biotechnology

IPO Date

2016-12-19

Stock Exchange

NASDAQ

Ticker

CKPT

The Enterprise Value as of December 2024 (TTM) for Checkpoint Therapeutics, Inc. (CKPT) is 165.69M

According to Checkpoint Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 165.69M. This represents a change of 141.24% compared to the average of 68.68M of the last 4 quarters.

Checkpoint Therapeutics, Inc. (CKPT) Historical Enterprise Value (quarterly & annually)

How has CKPT Enterprise Value performed in the past?

The mean historical Enterprise Value of Checkpoint Therapeutics, Inc. over the last ten years is 78.29M. The current 165.69M Enterprise Value has changed 21.06% with respect to the historical average. Over the past ten years (40 quarters), CKPT's Enterprise Value was at its highest in in the March 2017 quarter at 243.44M. The Enterprise Value was at its lowest in in the March 2015 quarter at 0.

Quarterly (TTM)
Annual

Average

78.29M

Median

68.54M

Minimum

29.97M

Maximum

181.72M

Checkpoint Therapeutics, Inc. (CKPT) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Checkpoint Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 209.36%

Maximum Annual Enterprise Value = 181.72M

Minimum Annual Increase = -81.80%

Minimum Annual Enterprise Value = 29.97M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202337.99M14.84%
202233.08M-81.80%
2021181.72M69.55%
2020107.18M209.36%
201934.65M15.59%
201829.97M-56.27%
201768.54M-50.07%
2016137.27M85.04%

Checkpoint Therapeutics, Inc. (CKPT) Average Enterprise Value

How has CKPT Enterprise Value performed in the past?

The current Enterprise Value of Checkpoint Therapeutics, Inc. (CKPT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

84.27M

5-year avg

78.92M

10-year avg

78.29M

Checkpoint Therapeutics, Inc. (CKPT) Enterprise Value vs. Peers

How is CKPT’s Enterprise Value compared to its peers?

Checkpoint Therapeutics, Inc.’s Enterprise Value is greater than Mustang Bio, Inc. (5.46M), greater than Reviva Pharmaceuticals Holdings, Inc. (70.91M), greater than Fortress Biotech, Inc. (60.71M), less than Kodiak Sciences Inc. (362.34M), greater than Fortress Biotech, Inc. (60.71M), greater than Avenue Therapeutics, Inc. (1.10M), greater than Pieris Pharmaceuticals, Inc. (-1407736.00), greater than Aileron Therapeutics, Inc. (22.86M), greater than CytomX Therapeutics, Inc. (55.32M), less than Instil Bio, Inc. (220.42M), greater than Neoleukin Therapeutics, Inc. (-6333315.00), greater than Spero Therapeutics, Inc. (-21358605.00), greater than Assembly Biosciences, Inc. (67.83M), greater than Achilles Therapeutics plc (-42104641.00), greater than Cue Biopharma, Inc. (42.98M), greater than Medicenna Therapeutics Corp. (113.60M), less than XOMA Corporation (290.55M), greater than ZIVO Bioscience, Inc. (78.24M), greater than Lumos Pharma, Inc. (24.19M),

Build a custom stock screener for Checkpoint Therapeutics, Inc. (CKPT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Checkpoint Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Checkpoint Therapeutics, Inc. (CKPT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Checkpoint Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Checkpoint Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Checkpoint Therapeutics, Inc. (CKPT)?

What is the 3-year average Enterprise Value for Checkpoint Therapeutics, Inc. (CKPT)?

What is the 5-year average Enterprise Value for Checkpoint Therapeutics, Inc. (CKPT)?

How does the current Enterprise Value for Checkpoint Therapeutics, Inc. (CKPT) compare to its historical average?